Search / 9 results found

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19, according to a study published in the Jan. 18 issue of the Journal of the American Medical Association.